Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
Instituto do Cancer do Estado de São Paulo
Bayer
Actuate Therapeutics Inc.
Eastern Cooperative Oncology Group
Memorial Sloan Kettering Cancer Center
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
University of California, Irvine
ViroMissile, Inc.
Dana-Farber Cancer Institute
Kaiser Permanente
University of Florida
Essen Biotech
MacroGenics
Avacta Life Sciences Ltd
Institut Curie
City of Hope Medical Center
Duke University
M.D. Anderson Cancer Center
Ocellaris Pharma, Inc.
University of Southern California
Eli Lilly and Company
Var2 Pharmaceuticals
University of Illinois at Chicago
Mayo Clinic
Tanabe Pharma America, Inc.
M.D. Anderson Cancer Center
Transgene
Bayer
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Hadassah Medical Organization
British Columbia Cancer Agency
Valo Therapeutics Oy
Institut Bergonié
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Washington University School of Medicine
Baylor College of Medicine
University of California, Irvine
University of California, Irvine
OncoC4, Inc.
German Cancer Research Center
Esperas Pharma Inc.
University Health Network, Toronto